Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion type Assertion NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_head.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion description "[Crizotinib (XALKORI?, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of adults with ALK-rearranged non-small-cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion evidence source_evidence_literature NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion SIO_000772 25413260 NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion wasDerivedFrom befree-2016 NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.
- NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_assertion wasGeneratedBy ECO_0000203 NP1238971.RAydFsFXrjw4fjB8q97B3RN4Z8B8kIXvqYa8e8QsFRD7w130_provenance.